Drug Safety

A Health Canada safety review assesses the potential risk of weight loss in children under age six who are prescribed off-label central nervous system stimulants for ADHD.

The clinical trial, published in JAMA Psychiatry Wednesday, found the treatment reduced depressive symptoms for more than 35% of participants, who received two 40-minute ketamine infusions over two weeks.

Joan Rubinger overcame a catastrophic biking accident that left her paralyzed to become an influential pain-relief specialist helping top-tier athletes get back on the field after acute and chronic injuries.

Often thought to be a thing of the past, syphilis is making a comeback in Canada with new presentations that should put clinicians on high alert.

A JAMA Oncology ‘patient page’ highlights key information to discuss with patients.

Study examines the association between inhaled corticosteroid continuation during the first trimester of pregnancy and maternal and neonatal outcomes.

Ascension Saint Thomas said four patients received potassium phosphate instead of the anesthetic mepivacaine.

Recently, I was approached by a colleague who had seen a patient with type 1 diabetes using a glucagon-like peptide-1 receptor agonist in combination with basal bolus insulin to manage their glucose levels.

A guide to acute and preventive outpatient therapy for children and adolescents.

Finally available in Canada, the first epinephrine nasal spray certainly meets a public need, but will have to prove its worth to last, according to three experts interviewed by Profession Santé.